ResMed (RMD) Tops Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
ResMed (RMD) share price 'may have overcompensated' - Morgan Stanley
October 27, 2023 11:38 AM EDTMorgan Stanley upgraded shares of ResMed (NYSE: RMD) to Overweight from Equal-Weight, lowering the price target on the stock to $169 from $180 per share in a note to clients Friday.
Analyst Sean Laaman told investors that their deep dive analysis on the obstructive sleep apnea (OSA) market suggests the... More
